Effect of Desflurane Versus Sevoflurane With Recent Bio-markers on Renal and Hepatic Functions

Study Overview
=================
Brief Summary
-----------------
Studying the effects of both inhalational anesthetics desflurane and sevoflurane on hepatic integrity and renal function, guided by recent blood and urine biomarkers in patients undergoing laparoscopic cholecystectomy surgery.

Official Title
-----------------
Evaluating the Effect of Desflurane Versus Sevoflurane With Recent Biomarkers of Renal and Hepatic Function in Laparoscopic Cholecystectomy Patients: A Prospective Randomized Double Blinded Study

Conditions
-----------------
Postoperative Complications

Intervention / Treatment
-----------------
* Diagnostic Test: Neutrophil Gelatinase-Associated Lipocalin (NGAL)
* Drug: Desflurane
* Drug: Sevoflurane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists (ASA) Class: I&II. Elective laparoscopic cholecystectomy. Age: 25-55 years. Gender: Both male and female. Body Mass Index (BMI): 18.5-24.9 km2-(Normal weight). Exclusion Criteria: Extremes of age. Abnormal hepatic function by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values outside the normal range. Abnormal renal function by blood urea nitrogen (BUN) and creatinine above the normal ranges. Hypertension, unstable angina pectoris or myocardial infarction within the last six months. Pregnancy and lactation. Bronchial asthma. Drug allergies. Alcohol or drug addiction. General anesthesia within the last three months.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sevoflurane<br>This group will receive sevoflurane as the maintenance inhalational anesthetic. | Diagnostic Test: Neutrophil Gelatinase-Associated Lipocalin (NGAL)<br>* The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.<br>Drug: Sevoflurane<br>* Sevoflurane<br>|
| Desflurane<br>This group will receive desflurane as the maintenance inhalational anesthetic. | Diagnostic Test: Neutrophil Gelatinase-Associated Lipocalin (NGAL)<br>* The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.<br>Drug: Desflurane<br>* Desflurane<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in serum Neutrophil gelatinase-associated lipocalin (NGAL) | Renal Biomarker | a change from baseline NGAL serum level at 6 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in serum Arginase | Hepatic biomarker | Baseline, first hour, six hours, after 24 hours | 
| Change in serum Cystatin-c | Hepatic biomarker | Baseline, first hour, six hours, after 24 hours | 
| Change in urine Netrin-1 | Renal biomarker | Baseline, first hour, six hours, after 24 hours | 
| Change in urine Kidney Injury Molecule | Renal biomarker | Baseline, first hour, six hours, after 24 hours | 
| Change in urine Interleukin-18 | cytokines | Baseline, first hour, six hours, after 24 hours | 
| Change in urine Alpha-Glutathione S-Transferase | Liver biomarker | Baseline, first hour, six hours, after 24 hours |